BioInvent Restructure, Reducing Workforce

Sweden’s BioInvent International has announced that they have been forced to restructure after the failure of an investigational antithrombotic in a mid-stage trial earlier this month. The corporation will restructure to have 68 permanent workers, in comparison to the present 89 permanent employee.  The reduction of the staff “and other reprioritisations” will create cost savings

Continue Reading